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While chemotherapy and targeted therapy are successful in inducing the remission of myeloid leukemia as acute
myeloid leukemia (AML) and chronic myeloid leukemia (CML), the disease remains largely incurable. This
observation is likely due to the drug resistance of leukemic cells, which are responsible for disease relapse. Myeloid
leukemia vaccines may most likely be beneficial for eradicating minimal residual disease after treatment with
chemotherapy or targeted therapy. Several targeted immunotherapies using leukemia vaccines have been heavily
investigated in clinical and preclinical trials. This review will focus on peptides and DNA vaccines in the context of
myeloid leukemias, and optimal strategies for enhancing the efficacy of vaccines based on myeloid leukemia
immunization are also summarized.
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While chemotherapy and targeted therapy are successful
at inducing myeloid leukemia remission, the disease re-
mains largely incurable. We have come to realize that
immunotherapy may result in a cure for the disease [1-5].
The goal of immunotherapy in myeloid leukemia is to
boost the patient immune system or confer immunity with
T cells, dendritic cells (DC), NK cells or monoclonal
antibodies.
Myeloid leukemia vaccines are most likely beneficial
for eradicating minimal residual disease after chemothe-
rapy or targeted therapy [6] although the suppressed im-
mune status of patients who receive these treatments
may influence their vaccine response. However, targeted
immunotherapy using leukemia vaccines has been hea-
vily investigated because these vaccines elicit specific
immune responses against leukemia cells while sparing
normal tissue. Optimal immunotherapy target antigens
are leukemia-specific antigens that are exclusively ex-
pressed by leukemia cells, are absent in normal tissues,
and can elicit potent immune responses; however, with
the exception of the BCR-ABL and PML-RARα fusion* Correspondence: tlinc@jnu.edu.cn; yangqiuli@hotmail.com
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reproduction in any medium, provided the orproteins, such leukemia-specific antigens are rare in other
myeloid leukemias. Leukemia-associated antigens (LAAs),
such as Wilms’ tumor 1 (WT1) antigen, proteinase-3
peptide, preferentially expressed antigen of melanoma
(PRAME), and receptor for hyaluronic acid-mediated
motility (RHAMM), are preferentially expressed by leuke-
mia cells but are also expressed by normal tissues, albeit
to a lesser degree [7].
Peptide vaccines have been developed against tumor-
specific and leukemia-associated self-antigens. Numer-
ous clinical trials involving peptide vaccines have been
performed with limited success [8-11]. It has become
clear that exogenous peptides alone fail to activate ef-
fective CD8+ T cell levels, and if induced, they tend to
be transient in patients with a weakened or tolerized im-
mune system. Therefore, DNA vaccines present an attract-
ive, alternative strategy for peptide vaccination [12-15].
DNA vaccines are bacterial plasmids constructed to
express an encoded protein following in vivo adminis-
tration and subsequent cell transfection. DNA vaccines
have many advantages for tumor antigens. First, to some
extent, encoded antigens can enter the processing and
presentation pathways of the immune system and induce
adaptive (antibodies, helper T cells, and cytotoxic lympho-
cytes (CTLs) ) and innate immune responses in a manner
similar to natural infection. Second, non-specific in-
nate immunity stimulation, which can act against tumord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vation of the innate immune system is the first step in the
induction of immunity against weak tumor antigens. In
fact, the presence of CD4+ T cells is also a critical re-
quirement for the generation of effector CTL responses
[16-21].
Results from animal models and initial clinical trials
are promising, but none have been translated into suc-
cessful standardized clinical treatments thus far, empha-
sizing the many differences between animal models and
patients [22-25]. This article will summarize peptide and
DNA vaccines in the context of myeloid leukemias.
Leukemia-specific antigens and LAA-derived
vaccines in myeloid leukemias
During the past decade, the understanding of the immu-
nology of myeloid leukemia has raised hopes that this
disease may be curable with immunotherapeutic approa-
ches. The optimal target antigens for immunotherapy
are leukemia-specific antigens. It is well known that
abnormal fusion proteins resulting from chromosomal
translocations can serve as relative leukemia-specific CTL
response targets including the BCR-ABL and PML-RARα
fusion proteins. Other attractive LAAs, including WT1
antigen, proteinase-3 peptide, PRAME, and RHAMM,
which are self-antigens overexpressed in leukemia cells,
can also serve as leukemia-associated targets for immune
responses [5,7].
BCR-ABL vaccines for BCR-ABL + leukemia
BCR-ABL fusion protein expression is unique to CML
leukemic cells and a portion of acute lymphocytic leu-
kemia (ALL) cells and derives from a t(9;22) transloca-
tion. Although imatinib is the standard treatment for
CML, not all patients reach complete cytogenetic re-
mission (CCR) and most maintain detectable disease at
the molecular level. Therefore, targeting the BCR-ABL-
derived p210 fusion protein may be an active and spe-
cific immunotherapy for improving outcome. Although
immune dysfunction has been demonstrated in many pa-
tients with CML [26], it has been recently reported that
immunological responses to the e14a2 BCR-ABL peptide
were statistically similar to that of 5 healthy subjects with
the same vaccination schedule as patients with CML [27].
A number of clinical trials have been performed with
vaccines based on the p210 BCR-ABL fusion protein. A
tumor-specific BCR-ABL breakpoint peptide-derived vac-
cine may be safely administered and reliably elicit mea-
surable peptide-specific immune responses in patients,
including those that received a bone marrow transplant,
interferon, or imatinib [28-31].
In particular, BCR-ABL peptide vaccination not only
stimulated specific tumor-specific immune responses in
patients with CML, it also allowed a reduction in theimatinib dose given and the benefit persistence of a
CML complete molecular response [32].
Breccia et al. reported the effects of p210 vaccination
(CMLVAX100) in two patients with residual molecu-
lar disease after high dose imatinib (600 or 800 mg).
CMLVAX100 comprised 100 μg each for five p210b3a2
breakpoint-derived peptides including four HLA class I
binding peptides (ATGFKQSSK, A11-binding; KQSS
KALQR, A3-binding; HSATGFKQSSK, A3 and A11-
binding; and GFKQ-SSKAL, B8-binding) and a 25 ami-
no acid peptide IVHSAT-GFKQSSKALQRP VASDFEP
(b3a2-25) with binding motifs for HLA class II DR1,
DR4, and DR11. In case #1, vaccination was begun in a
42-year-old male with chronic phase (CP) CML with inter-
mediate Sokal risk (b2a2 transcript type) 54 months after
beginning imatinib treatment with CML VAXb2a2-25, a
p210 b2a2 peptide (sequence: TVHSIPLTINKEEALQRP
VASDFEP), at a 100 μg dose, while in case #2, a 44-year-
old male with high Sokal risk CP CML (b3a2 transcript
type) had vaccination treatment started 20 months after
high dose imatinib therapy. The use of a transcript-related
vaccine enabled a reduction in the imatinib dose and the
concomitant realization of a persistent molecular res-
ponse [33].
In addition to the BCR-ABL peptide, a series of DNA
vaccines based on the BCR-ABL fusion gene were devel-
oped and tested in mice or in vitro. For example, plas-
mids encoding the complete BCR-ABL fusion gene were
capable of inducing protection against challenges from
B210 or 12B1 cells. No BCR-ABL-positive cells were
found in the liver, spleen or bone marrow of successfully
immunized animals [34].
PML-RARα vaccines for acute promyelocytic leukemia
Acute promyelocytic leukemia (APL) is associated with
a t(15;17) (q22;q11.2) chromosomal translocation and
involves the retinoic acid receptor α (RARα) gene on
chromosome 17 and its fusion partners including the
promyelocytic leukemia (PML) gene on chromosome 15.
The fusion gene encodes the corresponding fusion protein
thought to play a fundamental role in leukemogenesis.
The PML-RARα fusion protein is presented at the cell
surface by MHC molecules and may induce a tumor-
specific T-cell response in patients [35]. Therefore,
the PML-RARα fusion protein or fusion gene may be
selected as a specific leukemia antigen for inducing a spe-
cific immune response in patients with APL to further
prolong the remission duration and eradicate minimal re-
sidual disease.
Although there were few preclinical or clinical trials
involving vaccination with a PML-RARα peptide against
leukemic cells, DNA vaccines specifically targeting the
PML-RARα fusion protein can have a pronounced effect
on survival alone and in combination with all-trans
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nocompetent mice given DNA vaccines encoding various
portions of the BCR-1 PML-RARα fusion protein could
clear engrafted APL cells. These data demonstrate that
the tumor-specific immune clearance of APL cells oc-
curs in mice [38]. Another study indicated that a DNA
vaccine containing the PML-RARα segment and tetanus
fragment C (FrC) sequences could increase survival times
when used alone or in combination with all-trans retinoic
acid (ATRA) in a mouse APL model [37], which is similar
to a study that demonstrated that DNA vaccination
with ATRA confers the effective boosting of interferon-
gamma-producing and cytotoxic T-cells in leukemic
mice [39].
WT1 vaccines for myeloid leukemias
WT1 is an oncogenic protein expressed by the Wilms’
tumor gene that is overexpressed in the majority of AMLs
and CMLs. WT1 expression in progenitor cells is minimal
or absent, and the limited WT1 tissue expression in adults
suggests that WT1 may be a therapeutic leukemia target.
Results from an immune response WT1 vaccination
study provides immunologic, molecular, and preliminary
evidence for its potential clinical efficacy in AML patients
[40]. Ochsenreither et al. identified WT1-specific T-cell
clones from a patient with recurrent AML vaccinated with
a WT1 peptide (epitope: 126–134) who achieved a com-
plete remission (CR) lasting for 12 months. In addition, a
specific predominant T-cell clone was identified during
clinical remission, and it was increased in the PB and BM
after 8 vaccinations [41]. This predominant TCR Vβ11
clone could be found in other AML patients vaccinated
with the same WT1 peptide. Thus, WT1-specific T-cell
populations with proven clinical impact in WT1-
vaccinated patients may be considered as an immune re-
sponse biomarker after vaccination [42].
Increasing data demonstrate that WT1 peptide vaccines
may become a safe and cure-oriented therapy for patients
with CML who have residual disease. WT1 peptide vac-
cines may also be used for patients with CML who have
residual disease, particularly those who are resistant to
BCR-ABL tyrosine kinase inhibitors such as imatinib. In
an imatinib-treated patient with CML who was admi-
nistered a WT1 peptide vaccine, a decrease in BCR-ABL
mRNA levels was associated with an increased frequency
of WT1-specific CTLs in the patient’s peripheral blood
[43]. The WT1 peptide was administered 22 times over 18
months in a clinical trial for a CML patient who was being
treated with imatinib, and the BCR-ABL transcripts re-
markably decreased to a major molecular response level
after WT1 peptide administration, indicating its beneficial
effects on minimal residual disease [44].
WT1 as an immunotherapeutic target of a designed
DNA fusion vaccine was also evaluated. Plasmid DNAencoding the full-length murine WT1 gene was intra-
muscularly injected into C57BL/6 mice. Mice vaccinated
with WT1 plasmid DNA elicited CTLs against the WT1
protein, and the CTLs specifically killed WT1-expressing
tumor cells in a MHC class I-restricted manner [45]. An-
other preclinical experiment demonstrated that three p.
DOM-peptide vaccines, each encoding a different WT1-
derived, HLA-A2-restricted epitope, induced CTLs in
humanized transgenic mice expressing chimeric HLA-A2
without affecting hematopoietic stem cells, and these
CTLs killed human leukemia cells in vitro. These results
indicate that rationally designed DNA vaccines encoding
WT1-derived epitopes, particularly WT1 (37–45), have
the potential to induce/expand functional tumor-specific
cytotoxic responses in patients with cancer [46].
Potential LAA vaccines
PRAME
PRAME is overexpressed in many hematologic malig-
nancies, including AML [47] and CML [9], but is absent
in normal tissues, including hematopoietic progenitor
cells, and may be an appropriate candidate for T cell-
mediated immunotherapy. PRAME CTLs from healthy
donors and patients with CML were induced by HLA-
A*02-restricted PRAME-peptides under optimized cul-
ture conditions. These CTLs released IFNγ in response
to the PRAME peptides and lysed PRAME peptide-
loaded cells in an MHC-restricted fashion [9]. Moreover,
using professional and artificial antigen-presenting cells
loaded with a peptide library spanning the PRAME pro-
tein that consisted of 125 synthetic pentadecapeptides over-
lapping by 11 amino acids, polyclonal, PRAME-specific
CTL lines were successfully generated and elicited high-
avidity CTLs with a high proportion of the cells recogniz-
ing a previously uninvestigated HLA-A*02-restricted epi-
tope, P435-9mer (NLTHVLYPV). The cytotoxic activity of
PRAME-specific CTLs was directed not only against
leukemic blasts but also against leukemic progenitor cells,
which have been implicated in leukemia relapse. These
PRAME-directed CTLs did not affect normal hemato-
poietic progenitors, indicating that this approach may be
of value for PRAME+ hematologic malignancy immuno-
therapy [48].
PRAME peptides were first used in combination with
the WT1 peptide vaccine in the clinic, and vaccinations
could also improve the targeting of differentiated progeny
and suboptimally benefit patients responding to tyrosine
kinase inhibitors or enhance GVL effects in patients with
SCT [1].
PR1
PR1 is a 9–amino acid HLA-A*0201–restricted peptide
derived from proteinase 3, which is present at a high con-
centration in the primary granules of acute and chronic
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specific CTL responses that selectively killed leukemic
CD34+ cells in vitro [49], suggesting that it should be rela-
tively easy to boost these immune responses with vaccin-
ation. Highly encouraging preliminary data from a phase
1/2 study evaluating PR1 vaccination in patients with
myeloid leukemias were presented at the annual meeting
of the American Society of Hematology in 2004 [50].
In clinical trials, PR1 was frequently used with the
WT1 vaccine as a combination immunization strategy in
myeloid leukemia patients. For example, in a small trial,
8 patients received one subcutaneous dose each of the
PR1 and WT1 vaccines. CD8+ T cells directed against
PR1 or WT1 were detected in all patients after a sin-
gle vaccination. After vaccination, the emergence of
PR1- or specific CD8+ T cells was associated with a
decrease in WT1 mRNA expression as a marker for
minimal residual disease. This result indicated that a
combined PR1 and WT1 vaccine is immunogenic
and safe [51].RHAMM
RHAMM was identified as one of the most promising
LAAs in AML. Recently, limited clinical data demon-
strated that high-dose RHAMM-R3 peptide vaccination
in patients with AML could induce positive immuno-
logical responses [52]. Moreover, RHAMM not only
represents a promising LAA with specific T-cell res-
ponses in AML, it is also a probable prognostic factor if
it is assessed on blasts in situ [53]. These results sup-
port the further study of immunization strategies using
RHAMM alone or combination with other LAA vaccines
in leukemia patients.HSP
Heat shock proteins (HSPs) are highly conserved mole-
cules with many immunological functions. These pro-
teins are highly immunogenic and play an important
role in cancer immunotherapy. It was demonstrated that
HSP70PC vaccination is feasible and safe. When combi-
ned with imatinib mesylate, it is associated with immu-
nologic and potential clinical responses against CML-CP.
In a clinical trial, Hsp70PCs were purified from leuko-
pheresed peripheral blood mononuclear cells and admi-
nistered via eight weekly intradermal injections at 50μg /
dose without adjuvant. A significant correlation between
the clinical and immunologic responses was observed.
Cytogenetic responses were observed in the bone marrow
BCR-ABL + leukemia cells in 13 of 20 patients, despite
imatinib treatment for all except one patient. In addition,
the frequency of CML-specific, IFNγ-producing and
IFNγ-secreting NK cells in blood from 9 of 16 patients
increased [54].Enhancing immunogenicity
The ability of leukemia vaccines to elicit an immune re-
sponse to cancers has been well documented in clinical
trials and numerous animal models. However, effective
anti-leukemia immune responses are hampered by the
weak immunogenicity of leukemic cells. Most ongoing
clinical trials have confirmed that the immune response
to the majority of clinically tested DNA vaccines is poor,
and further optimization using adjuvant delivery systems
or prime-boost-based schedules is a major challenge.
Much effort has been made to identify agents that could
increase the immunogenicity of leukemic cells and acti-
vate the immune system. Genetic adjuvants are usually
cytokine genes, which provide general immune stimula-
tion and may also bias the immune response toward a
Th1 or Th2 type.
GM-CSF
Granulocyte-macrophage colony stimulating factor (GM-
CSF) is considered to be the most effective immunostimu-
lating factor [55]. For example, a GM-CSF vaccination
was combined with the WT1.126-134 peptide for patients
with AML. Seventeen patients with AML and 2 patients
with refractory anemia with excess blasts received a me-
dian of 11 vaccinations, and treatment was well tolerated.
The objective responses in the patients with AML have
been detected. WT1 mRNA levels decreased at least
3-fold from baseline in 35% of the patients. WT1-specific
T cells increased in the blood or bone marrow in a portion
of the patients with a median bone marrow frequency of
0.18% at baseline and 0.41% at week 18 [56].
IL-2
Interleukin-2 (IL-2) is one of the immunostimulatory
adjuvants used to improve the immune response to vac-
cine antigens by triggering the activation and prolifera-
tion of T cells. A DNA vaccine encoding the PML-RARα
fusion gene and the IL-2 gene demonstrated enhance im-
mune responses in PML-RARα-hIL-2-pIRES immunized
mice [57].
IL-7
IL-7 may influence the growth and differentiation of
T-cells, promote T-cell migration into tumor tissue and
up-regulate specific cellular immune responses. Vaccines
from a plasmid constructed with an mIL-7-BCR-ABL fu-
sion gene induced a better immune response in BALB/c
mice immunized with pV BCR-ABL /mIL-7 [58].
IL-12
IL12 is an essential cytokine for the generation of a Th1
response, NK cells and CTL stimulation. Cellular im-
munity could be enhanced by the pBudCE4.1-BCR-ABL-
GPI-mIL12 recombinant plasmid. Vaccination by this
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responses, significant levels of IL-2 and IFNγ, as well as
strong CTL responses in vitro. In a murine transplant
model, vaccinated mice demonstrated decreased leuke-
mia cell infiltration and reduced BCR-ABL transcript and
protein expression in bone marrow cells with a BCR-ABL-
GPI-mIL12 vaccine [59].
CpG
CpG-ODN is oligodeoxynucleotide containing one or
more unmethylated CpG dinucleotides. CpG-ODN could
directly and indirectly affect immune cells including DCs,
T-cells, B-cells, and NK cells. DNA vaccination against the
BCR-ABL oncoprotein with synthetic CpG-ODN and
levamisole (LMS) was tested in a mouse tumor model.
The overall antitumor effect was enhanced in the tumor
model. A high dose of CpG-ODN exhibited a superior
adjuvant effect in comparison with all combinations of
CpG-ODN and LMS [60].
Ubiquitin
Ubiquitin protein fusion results in its targeting to the
proteasome and processing through the MHC class I
pathway. Plasmids encoding an epitope from the WT1
gene (WT1-126) N-terminally fused to ubiquitin were
used to immunize a mouse model. Lymphoproliferative
responses following stimulation with the WT1-126 vac-
cine were observed in all of the immunized mice. More-
over, in vivo cytotoxicity assay results revealed the
specific lysis of target cells. Tumor growth decreased,
Th1 type cytokines were detected and WT1-126-specific,
IFNγ-producing lymphocytes developed in all immu-
nized groups [61].
In addition to the above-described vaccines, exosome-
based vaccines were recently reported to potentially be a
promising means of prolonging disease-free survival in
patients with APL after induction therapy [62]. Exo-
somes are a family of bioactive vesicles that play impor-
tant roles in antigen presentation.
Perspective
An important approach for prolonging remission duration
and eradicating minimal residual disease in leukemia is
immunotherapy. In myeloid leukemia, preclinical and cli-
nical trials involving vaccination with peptides derived
from a number of leukemia antigens, including WT1,
BCR-ABL, PML-RARα, PR1 or RHAMM, have demon-
strated evidence for immunogenicity, but there are limited
data concerning the clinical efficacy of vaccine-based
approaches. Most of the DNA vaccines for leukemia are
currently in the preclinical stage; thus no DNA cancer
vaccine has been licensed for use in humans [63].
Peptide and DNA vaccines derived from myeloid leu-
kemia-specific or leukemia-associated antigens are anattractive approach for immunotherapy to improve over-
all survival. However, optimal strategies for enhancing
the efficacy of vaccines based on myeloid leukemia im-
munization need to be improved. An efficacious vaccine
against cancers, including leukemias, will focus on mul-
tiple strategies for breaking self-tolerance, such as the
improvement of delivery [64,65], codon modification of
the antigen [46,66] and costimulation [36,37,57]. More-
over, activation of the powerful immune system to
continually attack emerging tumor cells is the goal. Thera-
peutic efficacy for advanced leukemia treatment surely
requires a more potent immune response than prophy-
laxis, although the presence of large quantities of antigens
provides a means for stimulation that may be lacking in
the prophylactic setting. Therapeutically vaccinating pa-
tients with leukemia, often in the setting of immune dam-
age or tolerance, requires a level of ingenuity beyond that
needed for prophylactic vaccines.
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